These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36579992)

  • 41. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.
    Touboul E; Buffat L; Belkacémi Y; Lefranc JP; Uzan S; Lhuillier P; Faivre C; Huart J; Lotz JP; Antoine M; Pène F; Blondon J; Izrael V; Laugier A; Schlienger M; Housset M
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):25-38. PubMed ID: 9989511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
    Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?
    Sun Y; Liu X; Cui S; Li L; Tian P; Liu S; Li Y; Yin M; Zhang C; Mao Q; Wang J
    Tumour Biol; 2016 Jul; 37(7):9555-63. PubMed ID: 26790445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
    Hortobagyi GN; Van Poznak C; Harker WG; Gradishar WJ; Chew H; Dakhil SR; Haley BB; Sauter N; Mohanlal R; Zheng M; Lipton A
    JAMA Oncol; 2017 Jul; 3(7):906-912. PubMed ID: 28125763
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
    Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark.
    Cronin-Fenton D; Kjærsgaard A; Nørgaard M; Amelio J; Liede A; Hernandez RK; Sørensen HT
    Breast Cancer Res Treat; 2018 Jan; 167(2):517-528. PubMed ID: 28948396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
    Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
    Bhowmik D; Song X; Intorcia M; Gray S; Shi N
    Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer.
    Delea TE; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
    J Thorac Oncol; 2006 Jul; 1(6):571-6. PubMed ID: 17409919
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 53. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
    Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Skeletal metastases in non-small cell lung cancer: a retrospective study.
    Tsuya A; Kurata T; Tamura K; Fukuoka M
    Lung Cancer; 2007 Aug; 57(2):229-32. PubMed ID: 17451841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
    Patel DN; Howard LE; De Hoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen ZW; Terris MK; Freedland SJ
    Cancer; 2020 Jul; 126(14):3274-3280. PubMed ID: 32374476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China.
    Yang Y; Ma Y; Sheng J; Huang Y; Zhao Y; Fang W; Hong S; Tian Y; Xue C; Zhang L
    Chin J Cancer; 2016 Apr; 35():40. PubMed ID: 27112196
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Axillary Nodal Metastases in Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma: Comparison of Node Detection and Morphology by Ultrasound.
    Chung HL; Tso HH; Middleton LP; Sun J; Leung JWT
    AJR Am J Roentgenol; 2022 Jan; 218(1):33-41. PubMed ID: 34319162
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.